Larimar Therapeutics, Inc.
Business
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for complex rare diseases using a proprietary cell penetrating peptide (CPP) platform. Its main product candidate is nomlabofusp, a subcutaneously administered recombinant fusion protein designed to deliver tissue frataxin to mitochondria for Friedreich’s ataxia. The company’s activities are organized around drug discovery and platform development, clinical development programs (Phase 1–2 and open-label studies), manufacturing partnerships and intellectual property/licensing. Larimar focuses on global regulatory and commercialization efforts in the United States, European Union, United Kingdom, Canada, Australia and other jurisdictions, utilizing clinical trial networks and third-party manufacturing and potential commercialization partners.
Summary from filing dated 2025-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 154 | 73 | 28 | 24 | 38 | |
| General and administrative | 18 | 18 | 14 | 12 | 12 | |
| Total operating expenses | 172 | 91 | 42 | 37 | 50 | |
| Loss from operations | −172 | −91 | −42 | −37 | −50 | |
| Other income, net | 7 | 10 | 5 | 1 | −171,000 | |
| Net loss | −166 | −81 | −37 | −35 | −51 | |
| Unrealized gain (loss) on marketable securities | −94,000 | 67,000 | 112,000 | −31,000 | −1,000 | |
| Total other comprehensive gain (loss) | −94,000 | 67,000 | 112,000 | −31,000 | −1,000 | |
| Total comprehensive loss | −166 | −81 | −37 | −35 | −51 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 85 | 33 | 27 | 27 | 70 | |
| Short-term marketable securities | 51 | 150 | 60 | 92 | — | |
| Prepaid expenses and other current assets | 5 | 12 | 3 | 2 | 2 | |
| Total current assets | 142 | 195 | 90 | 121 | 72 | |
| Property and equipment, net | 622,000 | 881,000 | 684,000 | 831,000 | 1 | |
| Operating lease right-of-use assets | 2 | 3 | 3 | 3 | 3 | |
| Restricted cash | 606,000 | 606,000 | 1 | 1 | 1 | |
| Other assets | 523,000 | 596,000 | 659,000 | 638,000 | 669,000 | |
| Total assets | 146 | 200 | 96 | 126 | 79 | |
| Accounts payable | 5 | 2 | 1 | 2 | 2 | |
| Accrued expenses | 58 | 21 | 7 | 8 | 7 | |
| Operating lease liabilities, current | 1 | 1 | 837,000 | 611,000 | 594,000 | |
| Total current liabilities | 65 | 24 | 10 | 11 | 9 | |
| Operating lease liabilities | 3 | 4 | 5 | 5 | 5 | |
| Total liabilities | 68 | 28 | 14 | 16 | 14 | |
| Commitments and contingencies (See Note 8) | — | — | — | — | — | |
| Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 250,000 and no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 83,090,392 and 63,815,065 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 83,000 | 64,000 | 43,000 | 43,000 | 18,000 | |
| Additional paid-in capital | 513 | 441 | 270 | 262 | 181 | |
| Accumulated deficit | −435 | −269 | −189 | −152 | −116 | |
| Accumulated other comprehensive gain | 54,000 | 148,000 | 81,000 | −31,000 | — | |
| Total stockholders' equity | 78 | 172 | 82 | 111 | 64 | |
| Total liabilities and stockholders' equity | 146 | 200 | 96 | 126 | 79 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −166 | −81 | −37 | −35 | −51 | |
| Stock-based compensation expense | 7 | 9 | 8 | 7 | 5 | |
| Lease expense | −281,000 | −189,000 | −82,000 | −46,000 | — | |
| Depreciation expense | 350,000 | 318,000 | 311,000 | 318,000 | 326,000 | |
| Amortization of premium on marketable securities | −2 | −5 | −2 | −774,000 | −14,000 | |
| Prepaid expenses and other current assets | 7 | −8 | −1 | −204,000 | 3 | |
| Accounts payable | 3 | 1 | −403,000 | 26,000 | −974,000 | |
| Accrued expenses | 38 | 13 | −1 | 2 | 749,000 | |
| Other assets | 73,000 | 63,000 | −21,000 | 31,000 | −250,000 | |
| Net cash used in operating activities | −113 | −71 | −34 | −28 | −42 | |
| Purchases of property and equipment | −91,000 | −515,000 | −164,000 | −100,000 | −333,000 | |
| Purchases of marketable securities | −84 | −228 | −101 | −134 | −8 | |
| Maturities of marketable securities | 184 | 143 | — | — | — | |
| Net cash provided by (used in) investing activities | 100 | −85 | 33 | −91 | 24 | |
| Proceeds from issuance of common stock, net of issuance costs | 65 | 162 | — | 75 | 20 | |
| Proceeds from exercise of stock options and warrants | — | 77,000 | 30,000 | — | — | |
| Net cash provided by financing activities | 65 | 162 | 30,000 | 75 | 20 | |
| Net increase in cash, cash equivalents and restricted cash | 52 | 6 | −76,000 | −43 | 2 | |
| Offering costs included in accounts payable and accrued expense | 100,000 | 50,000 | — | — | — | |
| Leased assets obtained in exchange for new operating lease liabilities | — | 465,000 | 790,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Larimar Therapeutics, Inc.'s CIK number?
Larimar Therapeutics, Inc.'s SEC CIK number is 0001374690 (1374690). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Larimar Therapeutics, Inc.'s SEC filings?
All of Larimar Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Larimar Therapeutics, Inc. last report earnings?
Larimar Therapeutics, Inc. (LRMR) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222746). This is Larimar Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Larimar Therapeutics, Inc.'s most recent earnings 8-K?
Larimar Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222746. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Larimar Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →